Fuisz develops easier to swallow dosage form

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmacology, Pharmaceutical formulation

US delivery technology firm Fuisz Pharma has developed an oral dosage form with improved compliance characteristics.

The new form, specific details of which have not yet been disclosed, is designed to be easier to shallow and less likely to adhere to mucosal surfaces than existing oral dosage forms.

The company claims that, in clinical studies, the new tablet and capsule shapes accelerated esophageal transit by as much as 80 per cent compared with standard oral dosage forms.

Adherence to the mucosa is the primary cause of transit failure according to managing partner Joseph Fuisz, who told in-Pharmatechnologist.com that shape is the key factor determining this interaction.

Our work showed that adhesion with mucosal surfaces is the primary driver of transit failure. We dramatically reduced the adhesion dynamic. Existing shapes use flat and long surfaces that readily mate to the esophageal mucosa.

Fuisz explained that the firm took existing tablet granulations and progressively modified tablet die and capsule mold shape until a form with improved characteristics was identified.

It also said that because little to no modification of the base formulation is needed, all characteristics aside from ‘swallowability’ and transit speed remain the same. This means, according to the firm, the new forms can be easily applied to existing products.


Mr Fuisz predicted that the company’s experience in dosage development, coupled with the new forms ‘tangible therapeutic benefits’ will make regulatory approval a relatively straightforward process.

Market introduction will be dictated by our partners as we like to stay in our place – drug delivery technologies -- as opposed to product. Interestingly, we have extended our designs to the presses and molds themselves.

He went on to predict that, initially at least, the consumer health sector would be most interested in the new design, describing it as being “most aggressive in pursuing new dosage forms.”

“[However] we will not view our project as successful unless we see entire product lines transition into this dosage form. One might say that this is product differentiation at its finest and perhaps just as important, at its simplest​. “

Related topics: Ingredients, Delivery technologies

Related news

Show more

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us


View more